Vishal Abiraj
Infectious Disease · Bamberg, SCNPI 1356652283
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 225 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Viiv Healthcare Company at 59.6% of the total. 2025 is the largest year on record at $1,044, 4.0 times the $261 reported in 2020.
Across 225 payments — averaging $20.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$3K
- Gilead$934
- Theratechnologies Inc.$499
- Merck$201
- Johnson & Johnson$79
- AbbVie$31
- plus $120 from 7 others
Across 7 payments — averaging $1407.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Theratechnologies Inc.$10K
What the payments were for
- Food & beverage$4,616100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 134 | $2,752 |
| Gilead | 42 | $934 |
| Theratechnologies Inc. | 22 | $499 |
| Merck | 12 | $201 |
| Johnson & Johnson(2 entities) | 5 | $79 |
| AbbVie | 2 | $31 |
| Insmed, Inc. | 2 | $25 |
| Novartis | 1 | $19 |
| Pfizer | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Janssen Scientific Affairs, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,616 in reported general payments places this provider in the 80th percentile of 102 infectious disease providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 208 | $799,342 |
| CabenuvaCabotegravir/Rilpivirine | 29 | $184,505 |
| Egrifta SvTesamorelin Acetate | 24 | $173,147 |
| DovatoDolutegravir Sodium/Lamivudine | 47 | $124,002 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 26 | $118,692 |
| JulucaDolutegravir/Rilpivirine | 22 | $74,164 |
| TivicayDolutegravir Sodium | 18 | $38,602 |
| DescovyEmtricitabine/Tenofov Alafenam | 13 | $27,297 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 29 | $651 |
| ValacyclovirValacyclovir Hcl | 11 | $261 |
| Fluticasone Propionate | 22 | $236 |
| Doxycycline Hyclate | 14 | $131 |
| Atorvastatin Calcium | 27 | $111 |
| Lisinopril | 32 | $102 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 12 | $98 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $934 | $826,640221 claims |
| Viiv Healthcare CompanyCabenuva, Dovato, Juluca, Tivicay | $2,752 | $421,272116 claims |
| Theratechnologies Inc.Egrifta Sv | $499 | $173,14724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 102 infectious disease providers in South Carolina.
Other infectious disease in Bamberg
- Timothy HenkelHilton Head Island$1.8M
- Toby FugateCharleston$136K
- John McKinnonCharleston$85K
- John SchrankGreenville$74K
- Rishika MotianiFlorence$43K
- John GnannCharleston$39K
- John SamiesOrangeburg$18K
- Akinwale OlatosiCamden$17K
- Robert BallNorth Charleston$14K
- Eunice GuzmanMyrtle Beach$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.